WO2002060471A3 - Ligands for receptor-like protein tyrosine phosphatases - Google Patents

Ligands for receptor-like protein tyrosine phosphatases Download PDF

Info

Publication number
WO2002060471A3
WO2002060471A3 PCT/GB2002/000403 GB0200403W WO02060471A3 WO 2002060471 A3 WO2002060471 A3 WO 2002060471A3 GB 0200403 W GB0200403 W GB 0200403W WO 02060471 A3 WO02060471 A3 WO 02060471A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
protein tyrosine
derivative
ligands
heparan sulphate
Prior art date
Application number
PCT/GB2002/000403
Other languages
French (fr)
Other versions
WO2002060471A2 (en
Inventor
Andrew William Stoker
Alexandru Radu Aricescu
Original Assignee
Ich Productions Ltd
Andrew William Stoker
Alexandru Radu Aricescu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0102354A external-priority patent/GB0102354D0/en
Application filed by Ich Productions Ltd, Andrew William Stoker, Alexandru Radu Aricescu filed Critical Ich Productions Ltd
Priority to AU2002228181A priority Critical patent/AU2002228181A1/en
Publication of WO2002060471A2 publication Critical patent/WO2002060471A2/en
Publication of WO2002060471A3 publication Critical patent/WO2002060471A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)

Abstract

The invention provides the use a heparan sulphate proteoglycan (HSPG) or a derivative or fragment or analogue thereof, or of heparin or a heparan sulphate, or a heparin derivative or heparan sulphate derivative for the manufacture of a medicament for use as a ligand of a receptor-like protein tyrosine phosphatase (RPTP). The invention has particular application in the treatment of nerve repair, nerve regeneration, nerve maturation and maturation of synaptic connections, and the prevention or delay or slowing down of the onset or progression of generation of neural tissue.
PCT/GB2002/000403 2001-01-30 2002-01-30 Ligands for receptor-like protein tyrosine phosphatases WO2002060471A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002228181A AU2002228181A1 (en) 2001-01-30 2002-01-30 Ligands for receptor-like protein tyrosine phosphatases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0102354A GB0102354D0 (en) 2001-01-30 2001-01-30 Ligands for receptor-like protein tyrosine phosphatases
GB0102354.8 2001-01-30
GB0123764A GB0123764D0 (en) 2001-01-30 2001-10-03 Ligands for receptor-like protein tyrosine phosphates
GB0123764.3 2001-10-03

Publications (2)

Publication Number Publication Date
WO2002060471A2 WO2002060471A2 (en) 2002-08-08
WO2002060471A3 true WO2002060471A3 (en) 2007-11-01

Family

ID=26245651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/000403 WO2002060471A2 (en) 2001-01-30 2002-01-30 Ligands for receptor-like protein tyrosine phosphatases

Country Status (1)

Country Link
WO (1) WO2002060471A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012219323A1 (en) * 2011-02-18 2013-09-05 President And Fellows Of Harvard College Molecular switch for neuronal outgrowth
AU2017286979B2 (en) * 2016-07-01 2023-04-27 Dignity Health Diagnostic or predictor of relapsing remitting multiple sclerosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006303A1 (en) * 1989-10-27 1991-05-16 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
WO1999062535A2 (en) * 1998-06-01 1999-12-09 University Of Maryland Biotechnology Institute Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases
WO2002009728A1 (en) * 2000-07-31 2002-02-07 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
WO2002083182A2 (en) * 2001-04-12 2002-10-24 Mcgill University The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006303A1 (en) * 1989-10-27 1991-05-16 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
WO1999062535A2 (en) * 1998-06-01 1999-12-09 University Of Maryland Biotechnology Institute Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases
WO2002009728A1 (en) * 2000-07-31 2002-02-07 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
WO2002083182A2 (en) * 2001-04-12 2002-10-24 Mcgill University The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ARICESCU A RADU ET AL: "Heparan sulfate proteoglycans are ligands for receptor protein tyrosine phosphatase sigma.", MOLECULAR AND CELLULAR BIOLOGY, vol. 22, no. 6, March 2002 (2002-03-01), March, 2002, pages 1881 - 1892, XP008014788, ISSN: 0270-7306 *
COOMBE D. R. ET AL: "Mac-1(CD11b/CD18) and CD45 mediate the adhesion of hematopoietic progenitor cells to stromal cell elements via recognition of stromal heparan sulfate", BLOOD, vol. 84, no. 3, 1 August 1994 (1994-08-01), pages 739 - 752, XP008015098 *
COTMAN S. L. ET AL: "Identification of extracellular matrix ligands for the heparan sulfate proteoglycan agrin", EXPERIMENTAL CELL RESEARCH, vol. 249, 1999, pages 54 - 64, XP001149331 *
HALFTER W. ET AL: "Collagen XVIII is a basement membrane heparan sulfate proteoglycan", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 39, 25 September 1998 (1998-09-25), pages 25404 - 25412, XP001149330 *
MAEDA N ET AL: "6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTP-beta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM)", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 35, 30 August 1996 (1996-08-30), pages 21446 - 21452, XP002222810, ISSN: 0021-9258 *
SASAKI T. ET AL: "New insights into the transmembrane protein tyrosine phosphatase CD45", INTERNATIONAL JOURNAL OF BIOCHEMISTRY &CELL BIOLOGY, vol. 33, 2001, pages 1041 - 1046, XP001148478 *
TONKS N.K. ET AL: "CD45, an integral membrane protein tyrosine phosphatase. Characterization of enzyme activity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 18, 25 June 1990 (1990-06-25), XP002234606 *
WANG Y. ET AT: "The receptor like protein tyrosine phosphatase HPTPa has two active catalytic domains with distinct substrate specificities", EMBO JOURNAL, vol. 10, no. 11, 1991, pages 3231 - 3237, XP001109783 *

Also Published As

Publication number Publication date
WO2002060471A2 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
EP2329842A3 (en) Interleukin-1 inhibitors in the treatment of diseases
PL350408A1 (en) Antithrombotic use of glycine betaine
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
WO2003057134A3 (en) Specific binding agents of human angiopoietin-2
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
WO2003087831A3 (en) Proteins involved in breast cancer
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
WO1999062535A3 (en) Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases
WO2001034596A3 (en) Pyrrolecarbonylimino derivatives as naaladase inhibitors
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2002060471A3 (en) Ligands for receptor-like protein tyrosine phosphatases
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
WO2003035048A3 (en) Methods for the treatment of osteoarthritis and compositions thereof
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
WO2003038130A8 (en) Therapeutics and diagnostics for disorders of erythropoiesis
DE69303305D1 (en) Means of treating chronic fatigue
ATE548048T1 (en) ONCOMODULIN FOR THE TREATMENT OF NEUROLOGICAL DISEASES
WO2003059248A3 (en) Pigment epithelium derived factor from human plasma and methods of use thereof
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
NO990450L (en) Treatment of mental disorders
WO2004005540A3 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
EP1143996A4 (en) Method of treating chronic cardiac disease
AU2185000A (en) Treatment of diseases involving cyst formation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP